0      0

320 - Castrate Resistant Prostate Cancer: The New Frontier in Treatment

‐ Oct 14, 2013 8:30am

In the last few years, advances in pharmacotherapy and immunotherapy have given new hope in castrate resistant prostate cancer with increases in overall survival up to 5.6 months. Advanced practice providers and nurses need to have an understanding of these treatments. This lecture will cover abiraterone, enzalutamide, sipuleucel-t, radium 223, docetaxel and cabazitaxel. There will also be discussion on current clinical trials showing promise.

Contact hours available until 10/11/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Faculty, Planners, and Authors Conflict of Interest Disclosure:
Planning Commitee Disclosures:
    Lee Ann Boyd, MSN, ARNO-C, CUNP / Presenter Bureau :Warner Chilcott
    Leanne Schimke, MSN, CRNP-C CUNP/ Presenter :Amgen-Xgeva, Warner Chilott

Speaker disclosures:
Leanne Schimke, MSN, CRNP-C, CUNP   
Presenter: Amgen-Xgeva, Warner Chilcott-Enablex

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.   

  • Discuss prostate cancer disease progression and identify the new drugs currently available and promising research for the treatment of castrate resistant prostate cancer.
  • Indicate the appropriate monitoring of individuals on abiraterone.
  • Describe how Sipuleucel-T is given and possible side effects that may be encountered.


You must be logged in and own this session in order to post comments.